Even though Sp1-controlled transcription has been viewed historically as a prominent target of mithramycin, ultimately, the effect of mithramycin on cancer cells is likely to be an indirect consequence of perturbing the function of Sp1 or some other transcription factor. This evidence concerns the gene SP1 and cancer.